K Lorenz1, T Keller2, B Noack1, A Freitag1, L Netuschil1, T Hoffmann1. 1. Department of Periodontology, Faculty of Medicine Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany. 2. ACOMED statistik, Leipzig, Germany.
Abstract
BACKGROUND AND OBJECTIVES: Severe periodontitis affects about 10% of the world population. In addition, associations between periodontitis and systemic diseases exist. Therefore, the diagnosis should be made quickly and at an early stage. Matrix metalloproteinase-8 (MMP-8) is the most prominent collagenase found in inflamed periodontal tissues. Its active form (aMMP-8) is increasingly used as a diagnostic biomarker. Aim of the present study is to evaluate the diagnostic accuracy of a novel aMMP-8 point-of-care (POC) test in comparison to the standard laboratory test to diagnose the disease rapidly and reliably. MATERIAL AND METHODS: In a prospective, mono-center, double-blinded, case-control study, participants with healthy gums (n = 35), gingivitis (n = 60) and periodontitis (n = 35) were investigated before and after therapy. Beside clinical variables for plaque and inflammation, aMMP-8 concentrations were determined in oral rinsing specimens by the enzyme-linked immunosorbent assay (ELISA) and by POC. Positive and negative percent agreements with their exact one-sided lower 95% confidence limits were calculated. RESULTS: Of 130 participants, 111 finished the study. Overall, positive percent agreements were 75.8% (57.7-88.9) before treatment and 73.7% (56.9-86.6) after treatment. Negative percent agreements were 92.8% (85.7-97.0) before and 93.3% (85.1-97.8) after treatment. Positive test results (POC and ELISA) ranged from 5.7% to 8.6% in healthy patients, 25.0-29.8% in patients with gingivitis and 40.0-48.1% in patients with periodontitis. Patients who had positive aMMP-8 test results (POC) showed higher scores for plaque and inflammation. CONCLUSIONS: The novel POC test to detect aMMP-8 has proved to agree strongly with the standard method, ELISA. The test can be recommended to screen patients at risk for periodontitis in dental offices, at the general practitioner and at specialists for associated diseases.
BACKGROUND AND OBJECTIVES: Severe periodontitis affects about 10% of the world population. In addition, associations between periodontitis and systemic diseases exist. Therefore, the diagnosis should be made quickly and at an early stage. Matrix metalloproteinase-8 (MMP-8) is the most prominent collagenase found in inflamed periodontal tissues. Its active form (aMMP-8) is increasingly used as a diagnostic biomarker. Aim of the present study is to evaluate the diagnostic accuracy of a novel aMMP-8 point-of-care (POC) test in comparison to the standard laboratory test to diagnose the disease rapidly and reliably. MATERIAL AND METHODS: In a prospective, mono-center, double-blinded, case-control study, participants with healthy gums (n = 35), gingivitis (n = 60) and periodontitis (n = 35) were investigated before and after therapy. Beside clinical variables for plaque and inflammation, aMMP-8 concentrations were determined in oral rinsing specimens by the enzyme-linked immunosorbent assay (ELISA) and by POC. Positive and negative percent agreements with their exact one-sided lower 95% confidence limits were calculated. RESULTS: Of 130 participants, 111 finished the study. Overall, positive percent agreements were 75.8% (57.7-88.9) before treatment and 73.7% (56.9-86.6) after treatment. Negative percent agreements were 92.8% (85.7-97.0) before and 93.3% (85.1-97.8) after treatment. Positive test results (POC and ELISA) ranged from 5.7% to 8.6% in healthy patients, 25.0-29.8% in patients with gingivitis and 40.0-48.1% in patients with periodontitis. Patients who had positive aMMP-8 test results (POC) showed higher scores for plaque and inflammation. CONCLUSIONS: The novel POC test to detect aMMP-8 has proved to agree strongly with the standard method, ELISA. The test can be recommended to screen patients at risk for periodontitis in dental offices, at the general practitioner and at specialists for associated diseases.
Authors: Ismo T Räisänen; Kehinde A Umeizudike; Pirjo Pärnänen; Pia Heikkilä; Taina Tervahartiala; Solomon O Nwhator; Andreas Grigoriadis; Dimitra Sakellari; Timo Sorsa Journal: Med Hypotheses Date: 2020-09-16 Impact factor: 1.538
Authors: Saeed Alassiri; Pirjo Parnanen; Nilminie Rathnayake; Gunnar Johannsen; Anna-Maria Heikkinen; Richard Lazzara; Peter van der Schoor; Jan Gerrit van der Schoor; Taina Tervahartiala; Dirk Gieselmann; Timo Sorsa Journal: Dis Markers Date: 2018-08-05 Impact factor: 3.434
Authors: Andreas Grigoriadis; Ismo T Räisänen; Pirjo Pärnänen; Taina Tervahartiala; Timo Sorsa; Dimitra Sakellari Journal: Clin Exp Dent Res Date: 2020-12-10
Authors: Ismo T Räisänen; Hanna Lähteenmäki; Shipra Gupta; Andreas Grigoriadis; Vaibhav Sahni; Juho Suojanen; Hanna Seppänen; Taina Tervahartiala; Dimitra Sakellari; Timo Sorsa Journal: Diagnostics (Basel) Date: 2021-04-15
Authors: Timo Sorsa; Saeed Alassiri; Andreas Grigoriadis; Ismo T Räisänen; Pirjo Pärnänen; Solomon O Nwhator; Dirk-Rolf Gieselmann; Dimitra Sakellari Journal: Diagnostics (Basel) Date: 2020-01-22
Authors: Jussi M Leppilahti; Ulla Harjunmaa; Jorma Järnstedt; Charles Mangani; Marcela Hernández; Taina Tervahartiala; Rodrigo Lopez; Ulla Ashorn; Per Ashorn; Dirk-Rolf Gieselmann; Timo Sorsa Journal: Diagnostics (Basel) Date: 2018-09-15
Authors: Gerhard Schmalz; Max Kristian Kummer; Tanja Kottmann; Sven Rinke; Rainer Haak; Felix Krause; Jana Schmidt; Dirk Ziebolz Journal: J Periodontal Implant Sci Date: 2018-08-31 Impact factor: 2.614
Authors: Ismo T Räisänen; Anna Maria Heikkinen; Eva Siren; Taina Tervahartiala; Dirk-Rolf Gieselmann; Gerrit-Jan van der Schoor; Peter van der Schoor; Timo Sorsa Journal: Diagnostics (Basel) Date: 2018-10-22